These findings identify Klotho/VEGFR2/PAK1 signal inhibition as a potential molecular targeting therapeutic intervention with anoikis resistance in advanced-stage HCC patients with metastasis. The gene discussed is KDR; the disease is hepatocellular carcinoma.